当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR.

Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR.

Abstract：

:The research question of this investigation is whether the reduction rate of Ki-67 after neoadjuvant chemotherapy (NAC) could indicate a survival in patients with non-pCR. A total of 455 patients had received NAC, and subsequent surgery was analyzed retrospectively. Patients with non-pCR were divided into three subgroups according to Ki-67 change: High-reduction (the absolute value of Ki-67 was reduced by >80 % compared with that prior to NAC), Low-reduction (the absolute value of Ki-67 was reduced by 0-80 % compared with that prior to NAC), and Increase group (the absolute value of Ki-67 was increased compared with that prior to NAC). The relapse-free survival (RFS) rates were compared among subgroups. pCR was achieved in 93 patients (20.4 %). In patients with non-pCR, the median reduction rate of Ki-67 was 60 %. A total of 15 % of patients were in the High-reduction, 63 % in the Low-reduction, and 22 % in the Increase group. The median follow-up period was 64.5 months. The 5-year RFS rates among the three groups were significantly different (p < 0.0001), and the differences were also observed in the HER2 (p = 0.033), triple-negative (p = 0.034), and luminal-like subtypes (p = 0.001). Patients in the High-reduction group showed comparable RFS to that of patients with pCR (p = 0.363). In patients with non-pCR, the reduction rate of Ki-67 after NAC significantly predicted RFS regardless of cancer subtypes. Therefore, patients who are non-pCR but who achieve a high reduction of Ki-67 can be expected to have a favorable prognosis similar to that of patients with pCR.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Matsubara N,Mukai H,Masumoto M,Sasaki M,Naito Y,Fujii S,Wada N

doi

10.1007/s10549-014-3084-6

subject

Has Abstract

pub_date

2014-08-01 00:00:00

pages

95-102

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

147

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy.

    abstract：:Metastasizing cancer cells can invade the extracellular matrix using plasma membrane protrusions, termed invadopodia, that contact and dissolve the matrix. Various membrane associated proteases localized on the invadopodial membranes are responsible for the extracellular matrix degradation. Work from our laboratory sh...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666155

    authors： Chen WT,Lee CC,Goldstein L,Bernier S,Liu CH,Lin CY,Yeh Y,Monsky WL,Kelly T,Dai M

    更新日期：1994-01-01 00:00:00

  • T-Type voltage gated calcium channels: a target in breast cancer?

    abstract：PURPOSE:The purpose of this review article is to discuss the potential of T-type voltage gated calcium channels (VGCCs) as drug targets in breast cancer. Breast cancer, attributable to the different molecular subtypes, has a crucial need for therapeutic strategies to counter the mortality rate. VGCCs play an important ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-018-4970-0

    authors： Bhargava A,Saha S

    更新日期：2019-01-01 00:00:00

  • Improved prognostication in small (pT1) breast cancers by image cytometry.

    abstract：:Feulgen-stained samples from 460 small (pT1) primary breast cancers were investigated by means of an image analysis system. Several DNA, morphometrical and textural parameters were evaluated for each patient, and the prognostic meaning of these parameters was then investigated by the Cox regression analysis. As progno...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00690188

    authors： Aubele M,Auer G,Falkmer U,Voss A,Rodenacker K,Rutquist LE,Höfler H

    更新日期：1995-01-01 00:00:00

  • Ethanol enhances erbB-mediated migration of human breast cancer cells in culture.

    abstract：:Growth factor systems (ligands and their receptors) are targets of ethanol toxicity. Inasmuch as alcohol consumption may increase the risk and development of breast cancer, we hypothesize that ethanol enhances cell migration by up-regulating the activities of erbB receptors. Of the three tested breast cancer cell line...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006436315284

    authors： Luo J,Miller MW

    更新日期：2000-09-01 00:00:00

  • Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer.

    abstract：:To report on a highly unusual case of a 20-year-old woman who presented with multifocal metaplastic breast cancer and was subsequently found to carry deleterious germline mutations in both BRCA1 and p53. Genetic testing was requested on an expedited basis to assist in surgical decision-making and BRCA1/2 and p53 genet...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3011-x

    authors： Bell K,Hodgson N,Levine M,Sadikovic B,Zbuk K

    更新日期：2014-07-01 00:00:00

  • Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.

    abstract：:Prognosis of early beast cancer is heterogeneous. Today, no histoclinical or biological factor predictive for clinical outcome after adjuvant anthracycline-based chemotherapy (CT) has been validated and introduced in routine use. Using DNA microarrays, we searched for a gene expression signature associated with metast...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1003-z

    authors： Bertucci F,Borie N,Roche H,Bachelot T,Le Doussal JM,Macgrogan G,Debono S,Martinec A,Treilleux I,Finetti P,Esterni B,Extra JM,Geneve J,Hermitte F,Chabannon C,Jacquemier J,Martin AL,Longy M,Maraninchi D,Fert V,Birnb

    更新日期：2011-06-01 00:00:00

  • Insulin-like growth factor expression in breast cancer epithelium and stroma.

    abstract：:The insulin-like growth factors (IGFs) are mitogens for many cancer cell types. In breast cancer cells, IGF-I and IGF-II have both been shown to stimulate cell proliferation. However, IGF-I mRNA has not been found in human breast cancer cell lines, making it unlikely that IGF-I is commonly expressed as an autocrine gr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF01833330

    authors： Cullen KJ,Allison A,Martire I,Ellis M,Singer C

    更新日期：1992-01-01 00:00:00

  • Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer.

    abstract：:This phase II study of liarozole fumarate (R85246, liarozole), a novel imidazole with retinomimetic and aromatase inhibitory effects, was designed to determine the efficacy and tolerability in postmenopausal women with advanced breast cancer in progression, to correlate these effects with hormonal levels, and to evalu...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1006320122711

    authors： Goss PE,Oza A,Goel R,Nabholtz JM,De Coster R,Bruynseels J,Reid C,Wadden N,Crump M,Tye LM

    更新日期：2000-01-01 00:00:00

  • Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.

    abstract：:Docetaxel is primarily metabolized by CYP3A4 and susceptible to alterations in clearance by CYP3A4 inhibition and induction. Imatinib is a CYP3A4 inhibitor. A phase I study of docetaxel and imatinib in metastatic breast cancer (MBC) was conducted to test the hypothesis that imatinib decreased docetaxel clearance. Doce...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1413-6

    authors： Connolly RM,Rudek MA,Garrett-Mayer E,Jeter SC,Donehower MG,Wright LA,Zhao M,Fetting JH,Emens LA,Stearns V,Davidson NE,Baker SD,Wolff AC

    更新日期：2011-05-01 00:00:00

  • Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.

    abstract：PURPOSE:Based on available phase III trial data, we performed a cost-effectiveness analysis of different treatment strategies that can be used in patients with newly diagnosed HER2-positive metastatic breast cancer (mBC). PATIENTS AND METHODS:We constructed a Markov model to assess the cost-effectiveness of four diffe...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3978-6

    authors： Diaby V,Adunlin G,Ali AA,Zeichner SB,de Lima Lopes G,Kohn CG,Montero AJ

    更新日期：2016-11-01 00:00:00

  • Trajectories of quality of life following breast cancer diagnosis.

    abstract：PURPOSE:Although quality of life (QoL) improves over time for most breast cancer survivors (BCS), BCS may show different patterns of QoL. This study sought to identify distinct QoL trajectories among BCS and to examine characteristics associated with trajectory group membership. METHODS:BCS (N = 653) completed baselin...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4677-2

    authors： Goyal NG,Levine BJ,Van Zee KJ,Naftalis E,Avis NE

    更新日期：2018-05-01 00:00:00

  • Association of RAD51C germline mutations with breast cancer among Bahamians.

    abstract：PURPOSE:RAD51C is known as an ovarian cancer gene; however, its role in breast cancer susceptibility is less clear. As part of a larger study, we assessed the role of germline RAD51C mutations in breast cancer development. METHODS:We studied 387 unselected, BRCA1- and BRCA2-negative, Bahamian breast cancer cases and 6...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05872-3

    authors： Bagherzadeh M,Szymiczek A,Donenberg T,Butler R,Hurley J,Narod SA,Akbari MR

    更新日期：2020-11-01 00:00:00

  • Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.

    abstract：PURPOSE:Clinical trials demonstrated adjuvant aromatase inhibitor treatment is superior for decreasing breast cancer recurrence risk over adjuvant tamoxifen treatment as early as 2001. Yet clinical use for adjuvant treatment was not recommended by the American Society of Clinical Oncology until 2004. Aromatase inhibito...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9558-z

    authors： Aiello EJ,Buist DS,Wagner EH,Tuzzio L,Greene SM,Lamerato LE,Field TS,Herrinton LJ,Haque R,Hart G,Bischoff KJ,Geiger AM

    更新日期：2008-02-01 00:00:00

  • Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

    abstract：:Molecular profiles of asynchronous breast cancer metastases are of clinical relevance to individual patients' treatment, whereas the role of profiles in synchronous lymph node metastases is not defined. The present study aimed to assess individual biomarkers and molecular subtypes according to the St Gallen classifica...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2617-8

    authors： Falck AK,Bendahl PO,Chebil G,Olsson H,Fernö M,Rydén L

    更新日期：2013-07-01 00:00:00

  • Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

    abstract：:The development of recombinant vaccines for specific immunotherapy of carcinoma represents a novel approach for the treatment of breast cancer and other tumor types. This article reviews the various parameters that should be considered in the development of recombinant vaccines. Several breast cancer associated antige...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF01803781

    authors： Schlom J,Kantor J,Abrams S,Tsang KY,Panicali D,Hamilton JM

    更新日期：1996-01-01 00:00:00

  • Quality control for estrogen receptor quantification by dextran-coated charcoal assay: a single laboratory's experience.

    abstract：:Wide fluctuations in results obtained by different laboratories for the content of estrogen receptors from a single source of tissue powder were reported by several investigators at the 1979 NCI Consensus Committee Meeting for Steroid Receptors in Breast Cancer and were further supported by data collected by our labor...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01805724

    authors： Raam S,Gelman R,Faulkner J,White GM,Cohen JL

    更新日期：1982-01-01 00:00:00

  • Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer.

    abstract：:Fresh organically grown pomegranates (Punica granatum L.) of the Wonderful cultivar were processed into three components: fermented juice, aqueous pericarp extract and cold-pressed or supercritical CO2-extracted seed oil. Exposure to additional solvents yielded polyphenol-rich fractions ('polyphenols') from each of th...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1014405730585

    authors： Kim ND,Mehta R,Yu W,Neeman I,Livney T,Amichay A,Poirier D,Nicholls P,Kirby A,Jiang W,Mansel R,Ramachandran C,Rabi T,Kaplan B,Lansky E

    更新日期：2002-02-01 00:00:00

  • Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.

    abstract：:Aurora kinases (AKs) regulate multiple components of mitotic cell division in eukaryotic cells. Aurora A is frequently amplified or overexpressed in breast cancer cells leading to aberrant chromosome segregation, genomic instability, and activation of oncogenic pathways. In the present studies, we determined the effec...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2171-9

    authors： Fiskus W,Hembruff SL,Rao R,Sharma P,Balusu R,Venkannagari S,Smith JE,Peth K,Peiper SC,Bhalla KN

    更新日期：2012-09-01 00:00:00

  • Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells.

    abstract：:The present study was undertaken to compare ROH growth responsiveness between normal human mammary epithelial cells (HMECs), estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cells, and assess whether this responsiveness is correlated with differences in ROH metabolism, particularly RA synthes...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1014815112078

    authors： Hayden LJ,Satre MA

    更新日期：2002-03-01 00:00:00

  • Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

    abstract：:The mutation pattern of breast cancer molecular subtypes is incompletely understood. The purpose of this study was to identify mutations in genes that may be targeted with currently available investigational drugs in the three major breast cancer subtypes (ER+/HER2-, HER2+, and Triple Negative). We extracted DNA from ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2035-3

    authors： Santarpia L,Qi Y,Stemke-Hale K,Wang B,Young EJ,Booser DJ,Holmes FA,O'Shaughnessy J,Hellerstedt B,Pippen J,Vidaurre T,Gomez H,Valero V,Hortobagyi GN,Symmans WF,Bottai G,Di Leo A,Gonzalez-Angulo AM,Pusztai L

    更新日期：2012-07-01 00:00:00

  • Factors influencing the use of extended adjuvant endocrine therapy.

    abstract：PURPOSE:Extending adjuvant endocrine therapy (ET) beyond 5 years has been shown to improve outcomes in breast cancer; however, limited data are available about if and why women pursue extended ET. The primary objective was to estimate the proportion of women who were willing to receive extended ET if recommended by the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05145-8

    authors： Kadakia KC,Kidwell KM,Barton DL,Schott AF,Hayes DF,Griggs JJ,Henry NL

    更新日期：2019-05-01 00:00:00

  • EpCAM expression is an indicator of recurrence in basal-like breast cancer.

    abstract：:Advances in the understanding of the molecular basis of breast cancer have necessitated a definition of more sensitive and specific indicators of prognosis that are central to the underlying cancer biology and that reflect the complicated and heterogeneous nature of the disease. This study investigates the expression ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1813-7

    authors： Agboola AJ,Paish EC,Rakha EA,Powe DG,Macmillan RD,Ellis IO,Green AR

    更新日期：2012-06-01 00:00:00

  • MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status.

    abstract：:The purpose of the study was to evaluate the use of metabolic phenotype, described by high-resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS), as a tool for prediction of histological grade, hormone status, and axillary lymphatic spread in breast cancer patients. Biopsies from breast cancer (...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9400-z

    authors： Bathen TF,Jensen LR,Sitter B,Fjösne HE,Halgunset J,Axelson DE,Gribbestad IS,Lundgren S

    更新日期：2007-08-01 00:00:00

  • Type I insulin-like growth factor receptor function in breast cancer.

    abstract：:Experimental evidence suggests an important role of the type I IGF receptor (IGF-IR) in breast cancer development. Breast tumors and breast cancer cell lines express the IGF-IR. IGF-IR levels are higher in cancer cells than in normal breast tissue or in benign mammary tumors. The ligands of the IGF-IR are potent mitog...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1005907101686

    authors： Surmacz E,Guvakova MA,Nolan MK,Nicosia RF,Sciacca L

    更新日期：1998-02-01 00:00:00

  • The impact of diabetes on survival following breast cancer.

    abstract：PURPOSE:It has been suggested that type 2 diabetes may affect breast cancer prognosis, possibly due to increased diabetes-related comorbidity, or direct effects of insulin resistance and/or hyperinsulinemia. The purpose of this study was to examine the impact of diabetes on survival following breast cancer. METHODS:Us...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9654-0

    authors： Lipscombe LL,Goodwin PJ,Zinman B,McLaughlin JR,Hux JE

    更新日期：2008-05-01 00:00:00

  • Autoradiographic localization of 3H-ORG 2058, a synthetic progestin, in the mammary glands of the baboon.

    abstract：:The uptake and retention of a radiolabeled synthetic progestin ORG 2058 by the mammary glands were examined in the baboon. Four estrogen-primed baboons were injected intravenously with 2.5 micrograms/kg body weight of 3H-ORG 2058. One animal received an additional injection of 2.5 mg/kg body weight of unlabeled proges...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806397

    authors： Weaker FJ,Sheridan PJ

    更新日期：1984-01-01 00:00:00

  • Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.

    abstract：AIMS:To examine the frequency of axillary lymph node (ALN) invasion of operable breast cancers by their combined oestrogen receptor (ER), progesterone receptor (PR) and HER-2 status. METHODS:2227 recently operated cases in one centre were retrieved from the Multidisciplinary Breast Centre database and stratified accor...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-9914-7

    authors： Van Calster B,Vanden Bempt I,Drijkoningen M,Pochet N,Cheng J,Van Huffel S,Hendrickx W,Decock J,Huang HJ,Leunen K,Amant F,Berteloot P,Paridaens R,Wildiers H,Van Limbergen E,Weltens C,Timmerman D,Van Gorp T,Smeets A,V

    更新日期：2009-01-01 00:00:00

  • Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.

    abstract：:Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive invasive ductal carcinoma accounts for ~45 % of invasive breast cancer (BC) diagnoses in the U.S. Despite reductions in BC mortality attributable to mammography screening and adjuvant hormonal therapy, an important challenge remains the development of...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3554-5

    authors： Buas MF,Rho JH,Chai X,Zhang Y,Lampe PD,Li CI

    更新日期：2015-09-01 00:00:00

  • Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).

    abstract：PURPOSE:To investigate the effects of cognitive function on discontinuation of hormonal therapy in breast cancer survivors ages 65+ ("older"). METHODS:Older breast cancer survivors with invasive, non-metastatic disease, and no reported cognitive difficulties were recruited from 78 Alliance sites between 2004 and 2011....

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-017-4353-y

    authors： Bluethmann SM,Alfano CM,Clapp JD,Luta G,Small BJ,Hurria A,Cohen HJ,Sugarman S,B Muss H,Isaacs C,Mandelblatt JS

    更新日期：2017-10-01 00:00:00

  • Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.

    abstract：PURPOSE:Genomic studies have revealed that genomic aberrations play important roles in the progression of this disease. The aim of this study was to evaluate the associations between clinical survival outcomes of the clonality and subclonality status of driver genes in breast cancer. METHODS:We performed an integrated...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05153-8

    authors： Lan Y,Zhao E,Luo S,Xiao Y,Li X,Cheng S

    更新日期：2019-05-01 00:00:00